Indian Ovarian Cancer diagnostics and therapeutics market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Ovarian cancer is one of the leading cancers in Indian women, is the fifth most common cause of death from cancer among women and has the highest mortality rate of all cancers of the female reproductive system. Ovarian cancer is a term attributed to the uncommon type of cancer that arises in the ovary of a woman from different types of cells. Ovarian cancer is caused due to the mutagenic changes in DNA. The risk for any woman acquiring ovarian cancer in her lifetime is 1 in 75, while her chance of death due to ovarian cancer is 1 in 100. Ovarian cancer is more prevalent among elderly women, making women over 55 a high-risk population. It is estimated that in India by the year 2020, the incidence of Ovarian cancer cases will be around 36200 and the prevalent cases will be around 100,000. Rising incidence of ovarian cancer, beneficial medical care reforms, increasing health awareness, low-cost base, and lack of regulatory and cultural inhibitions are key factors boosting the market in India.
Market Growth Drivers
The driving factors for the growth of the ovarian cancer diagnostics and therapeutics market in India include rising prevalence, persistent investment in R&D, growing geriatric population of women, increase in ovarian cancer cases, and ease of use of new drugs and therapies, the rise in healthcare expenditure are expected to boost the growth of ovarian cancer drugs market. Increased government funding is also propelling the growth of the market.